Glympse Bio, Inc.
CAMBRIDGE, United States · Founded 2017 · $68.7M raised
- Headquarters
- CAMBRIDGE, Massachusetts
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- glympsebio.com
- Total Funding
- $68.7M
- Last Round
- $46.7M Series BJun 2020
- Rounds
- 2
About
Glympse Bio developed engineered activity-based nanosensors (ABNs) to detect disease-associated protease activity in urine and blood, enabling non-invasive diagnostics for conditions including cancer and inflammatory diseases. The company merged with Sunbird Bio in 2023 to advance protein-based diagnostics for Alzheimer's and other neurological disorders.
Summary
Glympse Bio, Inc. is a Biotech company based in CAMBRIDGE, United States, founded in 2017. It has raised $68.7M in total across 2 rounds, most recently a $46.7M Series B round in Jun 2020. Investors include Section 32 and CRV (Charles River).
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2020
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...